VSEL therapy (or VSEL treatment) is one of the most exciting new anti-aging, regenerative medicine therapies to become available to patients and biohackers. A VSEL is a very small “embryonic-like” cell—a type of stem cell that has the greatest potential to regenerate and rejuvenate tissues throughout the entire human body. A powerful category of stem cells, a VSEL is so small that it can pass through areas of the body where other stem cells cannot. They are also very robust as when they reach their target they are known to be able to both rapidly multiply and grow in size to produce healing proteins.
Yes, VSELs are absolutely safe. Unlike embryonic regenerative cells, VSELs are what is known as pluripotent (can become nearly any tissue or organ) and therefore do not have the risk of tumor formation.
While VSELs are found in the bone marrow and blood, they are usually bound and thus stay intact and young, so even the elderly have these healthy and powerful stem cells. The VSELs that we use are autologous (derived from your own blood) which only enhances their safety profile.
Typically, VSELs are bound in plasma and are not very available for use in the body’s regenerative functions. Our colleague Dr. Todd Ovokaitys and his team at Johns Hopkins University Medical School developed the patented QiGen laser system to release millions of VSELs from the patient’s own plasma that can be used to restore and rejuvenate the body. In fact, Dr. Ovokaitys has worked with leading scientists such as Harvard University professor David Sinclair and has validated that this treatment can reverse biological and cellular age as measured by DNA methylation.
The age reversal effect on the body is typically 3 years with each VSEL treatment which can be measured within 6-12 weeks after each treatment. These results are the most remarkable that have been observed thus far for any method that can be used repeatedly. The profound effect of being able to turn back the biological clock throughout the body may allow a person to live a lot longer in a more youthful body. This advanced medical procedure has been performed thousands of times to date and we are proud to be selected as one of the few clinical sites in the country to be granted a QiGen system.
While some patients may experience relief of their symptoms and note improved energy and cognition after only one treatment, the number of VSEL treatments depends on the patient’s condition and longevity/anti-aging treatment goals and can be repeated safely and pain free with no recovery or down time. Dr. Greenberg and his medical team administer VSEL treatments under the stringent medical protocols prescribed by Dr. Ovokaitys.
These anti-aging VSEL treatments can be performed every few months and side effects are limited to fatigue and malaise in under 10% of the patients who received the procedure.
Using an innovative patented technology, this IV procedure utilizes a specially calibrated laser to direct the IV treatment of VSELs to target areas of the body that need regeneration. The laser treatment of the body is painless and safe for all areas of the body, including the eyes.
While VSELs are not approved by the FDA for treatment of any disease, they have been used to help patients with symptoms of a variety of conditions by promoting the regeneration of unhealthy tissue. The restoration process from VSELs is used as an anti-aging treatment, reversing aging by an average of three years per treatment. Patients with the following conditions or those interested in anti-aging treatments and maximizing hormonal function may benefit from VSEL treatment:
Dr. Ovokaitys published a clinical study of using VSELs to improve function in severe end stage heart failure. A normal heart pumps 50-65% of its blood each beat, and this percentage is called the ejection fraction. Less than 30% is considered severe heart failure. The study subjects had an average of a 21% ejection fraction and were all heart transplant candidates. Compared to other published work where intracoronary stem cells were delivered by invasive cardiac catheterization and gave an improvement of only 8% overall function in 6 months, our much simpler and safer intravenous delivery gave an average improvement of 50% in 3 months. Half the subjects improved off of the heart transplant list and 20% improved to nearly normal with just one treatment.
The prognosis in severe heart failure is only 30% one year survival, and little or no survival after 3 years. In contrast we showed an 80% survival rate after 6 years, which is unprecedented in this area. A heart transplant costs $1 million dollars and only 10% of candidates live long enough to get a transplant. Our procedure costs 99% less and nearly 100% of persons who could benefit could be able to receive the treatment.